Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

Table 3 Summary of second outcomes in this meta-analysis

Outcome of interest	RPC + BRPC				RPC				BRPC
Outcome of interest	Data sets	ES (95% CIs)	P value	I² (%)	Data sets	ES (95% CIs)	P value	I² (%)	Data sets	ES (95% CIs)	P value	I² (%)
DFS	7	0.66 (0.53–0.83)	< 0.001	0	3	0.80 (0.59–1.07)	0.137	0	2	0.44 (0.26–0.73)	0.002	0
Overall resection rate	12	0.64 (0.37–1.10)	0.104	60.0	6	0.50 (0.25–0.99)	0.048	60.4	5	0.69 (0.41–1.16)	0.159	36.1
R0 rate	19	2.83 (2.19–3.65)	< 0.001	40.2	8	1.95 (1.40–2.71)	< 0.001	22.3	6	4.75 (2.85–7.92)	< 0.001	16.4
Recurrence	12	0.65 (0.50–0.86)	0.003	0	4	0.77 (0.55–1.08)	0.131	0	5	0.41 (0.22–0.76)	0.005	10.2
pN+ rate	18	0.30 (0.20–0.43)	< 0.001	58.4	7	0.28 (0.21–0.38)	< 0.001	0	6	0.23 (0.07–0.75)	0.015	82.8

DFS disease-free survival, pN+ pathological positive lymph node, ES indicates effect size

ISSN: 1477-7819